TABLE 3:
|
|
|
|
---|---|---|---|
Temozolomide + Irinotecan |
Temozolomide + Irinotecan - Bevacizumab |
||
Characteristics |
Categories |
N (%) |
N (%) |
Best Response | Complete response | 0 (0.0) | 8 (17.4) |
Non-responder | 2 (4.2) | 1 (2.2) | |
Progressive disease | 16 (33.3) | 6 (13.0) | |
Partial response | 16 (33.3) | 14 (30.4) | |
Stable disease | 14 (29.2) | 17 (37.0) |